Jodrellin A is a bioactive compound. References: Koh SB, Wallez Y, Dunlop CR, Bernaldo de Quirós Fernández S, Bapiro TE, Richards FM, Jodrell DI. Mechanistic distinctions between CHK1 and WEE1 inhibition guide the scheduling of triple therapy with gemcitabine. Cancer Res. 2018 May 7. pii: canres.3932.2017. doi: 10.1158/0008-5472.CAN-17-3932. [Epub ahead of print] PubMed PMID: 29735549.

纯度：≥98%

CAS：124901-80-0